ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC

被引:4
|
作者
Chan, Sze Ling [1 ]
Low, Joshua Jun Wen [2 ]
Chia, Kee Seng [1 ,3 ,4 ,5 ,6 ]
Wee, Hwee-Lin [2 ,7 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore
[3] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Genome Inst Singapore, Singapore, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
[7] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
关键词
Warfarin; Pharmacogenetic testing; Attitudes; Asian; ADVERSE DRUG-REACTIONS;
D O I
10.1017/S026646231300069X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese. Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation. Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072). Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [41] Considerations of pharmacogenetic testing in children
    Haga, Susanne B.
    Solomon, Benjamin D.
    PHARMACOGENOMICS, 2016, 17 (09) : 975 - 977
  • [42] Understanding the pharmacogenetic approach to warfarin dosing
    Ingrid Glurich
    James K. Burmester
    Michael D. Caldwell
    Heart Failure Reviews, 2010, 15 : 239 - 248
  • [43] Systematic Review of Pharmacogenetic Warfarin Dosing
    Rianne M. F. van Schie
    Andrea L. Jorgensen
    Anthonius de Boer
    Anke-Hilse Maitland-van der Zee
    Journal of General Internal Medicine, 2009, 24 : 1171 - 1171
  • [44] Pharmacogenetic determinants of warfarin in the Indian population
    Shaik Mohammad Naushad
    Vijay Kumar Kutala
    Tajamul Hussain
    Salman A. Alrokayan
    Pharmacological Reports, 2021, 73 : 1396 - 1404
  • [45] Pharmacogenetic Testing for Guiding de novo Phenprocoumon Therapy in Stroke Patients
    Arnold, Marie-Luise
    Grond-Ginsbach, Caspar
    Kloss, Manja
    Di Mascio, Maria-Teresa
    Veltkamp, Roland
    Ringleb, Peter
    Lichy, Christoph
    CEREBROVASCULAR DISEASES, 2009, 28 (05) : 468 - 471
  • [46] Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    Flockhart, David A.
    O'Kane, Dennis
    Williams, Marc S.
    Watson, Michael S.
    Flockhart, David A.
    Gage, Brian
    Gandolfi, Roy
    King, Richard
    Lyon, Elaine
    Nussbaum, Robert
    O'Kane, Dennis
    Schulman, Kevin
    Veenstra, David
    Williams, Marc S.
    Watson, Michael S.
    GENETICS IN MEDICINE, 2008, 10 (02) : 139 - 150
  • [47] Factors Influencing Uptake of Pharmacogenetic Testing in a Diverse Patient Population
    O'Daniel, J.
    Lucas, J.
    Deverka, P.
    Ermentrout, D.
    Silvey, G.
    Lobach, D. F.
    Haga, S. B.
    PUBLIC HEALTH GENOMICS, 2010, 13 (01) : 48 - 54
  • [48] Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients
    Ramos, Alga S.
    Seip, Richard L.
    Rivera-Miranda, Giselle
    Felici-Giovanini, Marcos E.
    Garcia-Berdecia, Rafael
    Alejandro-Cowan, Yirelia
    Kocherla, Mohan
    Cruz, Iadelisse
    Feliu, Juan F.
    Cadilla, Carmed L.
    Renta, Jessica Y.
    Gorowski, Krystyna
    Vergara, Cunegundo
    Ruano, Gualberto
    Duconge, Jorge
    PHARMACOGENOMICS, 2012, 13 (16) : 1937 - 1950
  • [49] Pharmacist and physician perception of pharmacogenetic testing
    Xuereb, Althea Marie Bruno
    Wirth, Francesca
    Buhagiar, Luana Mifsud
    Camilleri, Liberato
    Azzopardi, Lilian M.
    Serracino-Inglott, Anthony
    INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 2022, 30 (02) : 188 - 191
  • [50] Validation of warfarin pharmacogenetic algorithms in clinical practice
    Marin-Leblanc, Melina
    Perreault, Sylvie
    Bahroun, Imen
    Lapointe, Mathieu
    Mongrain, Ian
    Provost, Sylvie
    Turgeon, Jacques
    Talajic, Mario
    Brugada, Ramon
    Phillips, Michael
    Tardif, Jean-Claude
    Dube, Marie-Pierre
    PHARMACOGENOMICS, 2012, 13 (01) : 21 - 29